Seroatlas · Human Serome Atlas

NAA30

N-alpha-acetyltransferase 30

Also known as: C14orf35, FLJ35355, MAK3, Mak3p, NAA30_HUMAN, NAT12

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q147X3
Gene: NAA30
Ensembl: ENSG00000139977
Chromosome: 14
Canonical length: 362 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Cytosol

OverviewNCBI Gene

Enables protein-N-terminal amino-acid acetyltransferase activity. Involved in protein stabilization. Located in cytosol and nucleus. Part of NatC complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

362 residues, UniProt reviewed canonical sequence.

>Q147X3|NAA30
     1  MAEVPPGPSS LLPPPAPPAP AAVEPRCPFP AGAALACCSE DEEDDEEHEG GGSRSPAGGE
    61  SATVAAKGHP CLRCPQPPQE QQQLNGLISP ELRHLRAAAS LKSKVLSVAE VAATTATPDG
   121  GPRATATKGA GVHSGERPPH SLSSNARTAV PSPVEAAAAS DPAAARNGLA EGTEQEEEEE
   181  DEQVRLLSSS LTADCSLRSP SGREVEPGED RTIRYVRYES ELQMPDIMRL ITKDLSEPYS
   241  IYTYRYFIHN WPQLCFLAMV GEECVGAIVC KLDMHKKMFR RGYIAMLAVD SKYRRNGIGT
   301  NLVKKAIYAM VEGDCDEVVL ETEITNKSAL KLYENLGFVR DKRLFRYYLN GVDALRLKLW
   361  LR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NAA30 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.48
Highest tissue expression: 30 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 30 nTPM
tongue: 26 nTPM
testis: 17 nTPM
liver: 16 nTPM
bone marrow: 14 nTPM
cerebral cortex: 14 nTPM

Single-cell type

late primary spermatocytes: 129 nCPM
early spermatids: 95 nCPM
early primary spermatocytes: 56 nCPM
oocytes: 46 nCPM
late spermatids: 45 nCPM
sertoli cells: 45 nCPM

Immune cell

non-classical monocyte: 2.8 nTPM
NK-cell: 2.4 nTPM
memory CD8 T-cell: 1.8 nTPM
T-reg: 1.7 nTPM
gdT-cell: 1.2 nTPM
MAIT T-cell: 1.2 nTPM

Brain region

hypothalamus: 24 nTPM
cerebral cortex: 22 nTPM
basal ganglia: 21 nTPM
cerebellum: 20 nTPM
thalamus: 19 nTPM
midbrain: 18 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NAA30.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 48 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Lethal multiystemic syndrome

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.23
gnomAD pLI: 0.99
gnomAD missense Z: 1.61
DepMap mean gene effect: -0.37
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

protein stabilization

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NAA30 as an antibody target. Whether an autoantibody or antibody against NAA30 could matter depends on whether native NAA30 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NAA30 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NAA30 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...